BioCentury
ARTICLE | Top Story

Abbott meets Street

July 9, 2004 7:00 AM UTC

ABT reported second quarter EPS of $0.54, meeting the Street's estimate and up 15% from EPS of $0.47 in the same period last year. Second quarter global sales were $4.7 billion, up 14% compared with the same period last year. U.S. pharmaceutical sales grew 12% to $1.6 billion, driven by rheumatoid arthritis (RA) drug Humira adalimumab, TriCor fenofibrate to lower triglycerides and Omnicef cefdinir to treat bacterial infections.

Global second quarter Humira sales were $203 million, an increase of 155% quarter over quarter. U.S. sales of the drug were $138 million and ex-U.S. sales were $65 million. ABT raised its full year 2004 worldwide sales estimate for Humira to more than $800 million from more than $700 million. ...